RPESP Blocking Peptide
- Known as:
- RPESP Blocking Peptide
- Catalog number:
- 33r-5349
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- RPESP Blocking Peptide
Related genes to: RPESP Blocking Peptide
- Gene:
- SBSPON NIH gene
- Name:
- somatomedin B and thrombospondin type 1 domain containing
- Previous symbol:
- C8orf84
- Synonyms:
- RPESP
- Chromosome:
- 8q21.11
- Locus Type:
- gene with protein product
- Date approved:
- 2009-01-09
- Date modifiied:
- 2015-11-09
Related products to: RPESP Blocking Peptide
Related articles to: RPESP Blocking Peptide
- Diabetic kidney disease (DKD) is a severe global complication of diabetes, yet its molecular mechanisms remain incompletely understood. This study aimed to investigate the role of protein glycosylation in DKD pathogenesis and its association with gene expression changes, with the goal of identifying diagnostic biomarkers and personalized therapeutic targets. - Source: PubMed
Publication date: 2025/08/18
Liu ZiyangQin ZengyuanBai WenxinWang ShashaHuang ChunlingLi NaYan LeiGu YueShao Fengmin - Bladder cancer poses severe threats to human health due to its aggressive nature and resistance to drug treatment; however, the underlying mechanisms have not been fully investigated. In the present study, we identify SBSPON (Somatomedin B and Thrombospondin Type 1 Domain Containing) as a novel tumor suppressor. The expression of SBSPON was downregulated in bladder cancer and correlated with poor overall survival. SBSPON suppressed the proliferation and migration ability of bladder cancer cells , and inhibited tumor growth of bladder cancer cells . Genetic ablation of in mice significantly accelerated the progression of N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) induced bladder cancer. Mechanistically, SBSPON is a novel HSPA5 binding glycoprotein. SBSPON functioned through binding to HSPA5 and inhibiting its membrane translocation, resulting in an inactivated AKT signaling pathway. More importantly, SBSPON inhibited the cisplatin resistance of bladder cancer cells by reducing the inhibitory effect of HSPA5 on apoptosis. In summary, the novel glycoprotein SBSPON functions as a tumor suppressor and inhibits resistance to cisplatin in bladder cancer. This may provide novel therapeutic strategies for bladder cancer treatment. - Source: PubMed
Publication date: 2025/07/11
Ni BeibeiLi ShiZhao LanGao LinLuo LiyaZhang JunwenXie XinaZhu YuqiYang WeiMin ShashaWang YanLi XianxinCai ZhimingSpeakman John RLi Zesong - Peripartum cardiomyopathy (PPCM) is a form of heart failure that develops in the late stages of pregnancy or early postpartum. It accounts for 60% of deaths due to pregnancy-related cardiogenic shock, making it a significant cause of maternal mortality. Known risk factors include advanced maternal age, multiple gestation, African descent, preeclampsia, low socioeconomic status, and diabetes. Genetic factors, including truncating mutations in the TTN gene, have also been implicated in increasing susceptibility to PPCM. This narrative review synthesizes the literature from 2005 to 2025, examining both clinical and preclinical studies on genetic risk factors for PPCM. This review of 17 studies (13 clinical and 4 preclinical) reveals that genetic mutations, particularly in the TTN gene, play a significant role in PPCM risk. Additionally, alterations in genes related to sarcomere stability (filamin C), myosin function (MYH6, MYH7), heat shock proteins (BAG3, Hsp20, Hspb16), desmosome proteins, oxidative stress (signal transducer and activator of transcription 3, PGC-1α), immunity, and metabolism (CRTAM, SH2D1B, SBSPON, TNS3, PLN, SERCA) also contribute to an increased risk for PPCM. Many of these genes have been previously noted in dilated cardiomyopathy, suggesting that PPCM may be a form of dilated cardiomyopathy. This work expands on previous reviews by integrating both clinical and preclinical studies, while also addressing a gap in the literature with an updated synthesis of current findings on this topic. This work begins to lay the foundation for the potential implementation of genetic screening for PPCM, offering insights that could enable more proactive and personalized clinical care for at-risk individuals. - Source: PubMed
Publication date: 2025/06/18
Seidman LaurenSathi NicholasFrishman William H - Pregnancy imposes significant cardiovascular adaptations, including progressive increases in plasma volume and cardiac output. For most women, this physiological adaptation resolves at the end of pregnancy, but some women develop pathological dilatation and ultimately heart failure late in pregnancy or in the postpartum period, manifesting as peripartum cardiomyopathy (PPCM). Despite the mortality risk of this form of heart failure, the molecular mechanisms underlying PPCM have not been extensively examined in human hearts. - Source: PubMed
Publication date: 2024/11/08
Li AmyFang BernardLi MengboKoay Yen ChinMalecki CassandraHunter BenjaminHarney DylanDos Remedios Cristobal GLarance MarkO'Sullivan John FLal Sean - The aim of this study was to construct a glycolysis-related long noncoding RNA (lncRNA) signature to predict the prognosis of patients with gastric cancer (GC). Glycolysis-related genes were obtained from the Molecular Signatures Database (MSigDB), lncRNA expression profiles and clinical data of GC patients were obtained from The Cancer Genome Atlas database (TCGA). Furthermore, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate Cox regression analysis were used to construct prognostic glycolysis-related lncRNA signature. The specificity and sensitivity of the signature was verified by receiver operating characteristic (ROC) curves. We constructed a nomogram to predict the 1-year, 3-year, and 5-year survival rates of GC patients. Besides, the relationship between immune infiltration and the risk score was analyzed in the high and low risk groups. Multi Experiment Matrix (MEM) was used to analyze glycolysis-related lncRNA target genes. R "limma" package was used to analyze the mRNA expression levels of the glycolysis-related lncRNA target genes in TCGA. Gene set enrichment analysis (GSEA) was employed to further explore the biological pathways in the high-risk group and the glycolysis-related lncRNA target gene. A prognostic signature was conducted based on nine glycolysis-related lncRNAs, which are AL391152.1, AL590705.3, RHOXF1-AS1, CFAP61-AS1, LINC00412, AC005165.1, AC110995.1, AL355574.1 and SCAT1. The area under the ROC curve (AUC) values at 1-year, 3-year, and 5-year were 0.765, 0.828 and 0.707 in the training set, and 0.669, 740 and 0.807 in the testing set, respectively. In addition, the nomogram could efficaciously predict the 1-year, 3-year, and 5-year survival rates of the GC patients. Then, we discovered that GC patients with high-risk scores were more likely to respond to immunotherapy. GSEA revealed that the signature was mainly associated with the calcium signaling pathway, extracellular matrix (ECM) receptor interaction, and focal adhesion in high-risk group, also indicated that SBSPON is related to aminoacyl-tRNA biosynthesis, citrate cycle, fructose and mannose metabolism, pentose phosphate pathway and pyrimidine metabolism. Our study shows that the signature can predict the prognosis of GC and may provide new insights into immunotherapeutic strategies. - Source: PubMed
Publication date: 2022/11/07
Zeng JianminLi ManDai KefanZuo BingyuGuo JianhuiZang Lu